商业化推广全球稳步推进

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [2] Core Views - The company has made significant progress in the global commercialization of its products, particularly BAT1806 (Tocilizumab), which has received positive opinions from the European Medicines Agency (EMA) and has been approved by the U.S. FDA, marking it as the first monoclonal antibody drug developed by a Chinese company to gain such approval [5][6] - The company reported a revenue of 705 million yuan for 2023, representing a year-on-year growth of 54.86%, while the revenue for Q1 2024 was 162 million yuan, showing a growth of 4.30% [4] - The company is expected to achieve revenues of 1.22 billion yuan, 1.65 billion yuan, and 2.06 billion yuan for the years 2024, 2025, and 2026 respectively, indicating a strong growth trajectory [6] Financial Performance Summary - The company reported a net profit attributable to shareholders of -119 million yuan for 2023, with a net profit of -123 million yuan after deducting non-recurring gains and losses [4] - The projected revenue growth rates for the upcoming years are 73.42% for 2024, 34.82% for 2025, and 24.98% for 2026 [7] - The earnings per share (EPS) is expected to improve from -0.95 yuan in 2023 to 1.22 yuan in 2026 [7]